170 related articles for article (PubMed ID: 10326962)
1. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs.
Yanni JM; Weimer LK; Sharif NA; Xu SX; Gamache DA; Spellman JM
Arch Ophthalmol; 1999 May; 117(5):643-7. PubMed ID: 10326962
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases.
Sharif NA; Xu SX; Miller ST; Gamache DA; Yanni JM
J Pharmacol Exp Ther; 1996 Sep; 278(3):1252-61. PubMed ID: 8819509
[TBL] [Abstract][Full Text] [Related]
3. Olopatadine (AL-4943A): ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis.
Sharif NA; Xu SX; Yanni JM
J Ocul Pharmacol Ther; 1996; 12(4):401-7. PubMed ID: 8951676
[TBL] [Abstract][Full Text] [Related]
4. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: effects of new topical ocular drugs.
Yanni JM; Sharif NA; Gamache DA; Miller ST; Weimer LK; Spellman JM
Acta Ophthalmol Scand Suppl; 1999; (228):33-7. PubMed ID: 10337430
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of topical anti-allergic eye drops on human conjunctiva-derived cells: responses to histamine and IFN gamma and toxicological profiles.
Pauly A; Brignole-Baudouin F; Guenoun JM; Riancho L; Rat P; Warnet JM; Baudouin C
Graefes Arch Clin Exp Ophthalmol; 2007 Apr; 245(4):534-46. PubMed ID: 16900358
[TBL] [Abstract][Full Text] [Related]
6. Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use.
Yanni JM; Stephens DJ; Parnell DW; Spellman JM
J Ocul Pharmacol; 1994; 10(4):665-75. PubMed ID: 7714410
[TBL] [Abstract][Full Text] [Related]
7. Histamine-stimulated cytokine secretion from human conjunctival epithelial cells: inhibition by the histamine H1 antagonist emedastine.
Weimer LK; Gamache DA; Yanni JM
Int Arch Allergy Immunol; 1998 Apr; 115(4):288-93. PubMed ID: 9566351
[TBL] [Abstract][Full Text] [Related]
8. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent.
Yanni JM; Stephens DJ; Miller ST; Weimer LK; Graff G; Parnell D; Lang LS; Spellman JM; Brady MT; Gamache DA
J Ocul Pharmacol Ther; 1996; 12(4):389-400. PubMed ID: 8951675
[TBL] [Abstract][Full Text] [Related]
9. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
Netland PA; Leahy C; Krenzer KL
Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
[TBL] [Abstract][Full Text] [Related]
10. Histamine-induced cytokine production and ICAM-1 expression in human conjunctival fibroblasts.
Leonardi A; DeFranchis G; De Paoli M; Fregona I; Plebani M; Secchi A
Curr Eye Res; 2002 Sep; 25(3):189-96. PubMed ID: 12607189
[TBL] [Abstract][Full Text] [Related]
11. Human conjunctival epithelial cells express histamine-1 receptors coupled to phosphoinositide turnover and intracellular calcium mobilization: role in ocular allergic and inflammatory diseases.
Sharif NA; Xu SX; Magnino PE; Pang IH
Exp Eye Res; 1996 Aug; 63(2):169-78. PubMed ID: 8983974
[TBL] [Abstract][Full Text] [Related]
12. Interactions of olopatadine and selected antihistamines with model and natural membranes.
Brockman HL; Momsen MM; Knudtson JR; Miller ST; Graff G; Yanni JM
Ocul Immunol Inflamm; 2003 Dec; 11(4):247-68. PubMed ID: 14704897
[TBL] [Abstract][Full Text] [Related]
13. Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies.
Sharif NA; Su SX; Yanni JM
J Ocul Pharmacol; 1994; 10(4):653-64. PubMed ID: 7714409
[TBL] [Abstract][Full Text] [Related]
14. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells.
Yanni JM; Miller ST; Gamache DA; Spellman JM; Xu S; Sharif NA
Ann Allergy Asthma Immunol; 1997 Dec; 79(6):541-5. PubMed ID: 9433371
[TBL] [Abstract][Full Text] [Related]
15. Niflumic acid reduces histamine-induced interleukin-6 and -8 expression in human conjunctival epithelial cells.
Lim SA; Hwang KY; Chung SH
Ophthalmic Res; 2013; 50(4):192-6. PubMed ID: 24030317
[TBL] [Abstract][Full Text] [Related]
16. Olopatadine inhibits anti-immunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells.
Cook EB; Stahl JL; Barney NP; Graziano FM
Ann Allergy Asthma Immunol; 2001 Nov; 87(5):424-9. PubMed ID: 11730187
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the clinical efficacy of pheniramine maleate/naphazoline hydrochloride ophthalmic solution and olopatadine hydrochloride ophthalmic solution in the conjunctival allergen challenge model.
Greiner JV; Udell IJ
Clin Ther; 2005 May; 27(5):568-77. PubMed ID: 15978305
[TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
Abelson MB; Greiner JV
Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
[TBL] [Abstract][Full Text] [Related]
19. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
Kida T; Fujii A; Sakai O; Iemura M; Atsumi I; Wada T; Sakaki H
Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
[TBL] [Abstract][Full Text] [Related]
20. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity.
Abelson MB; Spitalny L
Am J Ophthalmol; 1998 Jun; 125(6):797-804. PubMed ID: 9645717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
